title: Terlipressin and albumin combination treatment in hepatorenal syndrome.
abstract: OBJECTIVE
  Hepatorenal syndrome (HRS) is a severe complication of cirrhosis, leading to death in nearly all of cases in the absence of liver transplantation. Several treatments have been attempted as a bridge to liver transplantation. Promising results have been shown with terlipressin and albumin treatment. The aim of this retrospective study was to evaluate our patients with HRS and the effects of combined therapy of terlipressin and albumin on survival.
  
  
  METHODS
  Twenty two patients (15 with type 1 HRS and 7 with type 2 HRS) who were admitted to our clinic between 1996 and 2001, were enrolled. All 7 pts with type 1 HRS were given terlipressin 2-4 mg/day and albumin 2 x 20 g/day for 6 days (range: 3-14).
  
  
  RESULTS
  Rate of mortality in hospital was 64% in total group, 80% in type 1 and 29% in type 2. Additionally rate of death was 57% in type 1 patients that received terlipressin+albumin and 100% in unreceived ones (p<0.05).
  
  
  CONCLUSIONS
  In this retrospective study, survival following improvement in renal function was noted in nearly half (43%) of type 1 patients that received terlipressin+albumin. Parameters associated with response to terlipressin+albumin and increased survival should be defined better in a large cohort of cirrhotic patients with HRS.
authors.affiliation: Istanbul University, Istanbul Medical Faculty, Gastroenterohepatology Department, Turkey.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Danalioglu
authors.forename: Yilmaz
authors.initials: Y
authors.lastname: Cakaloglu
authors.forename: Cetin
authors.initials: C
authors.lastname: Karaca
authors.forename: Nevzat
authors.initials: N
authors.lastname: Aksoy
authors.forename: Filiz
authors.initials: F
authors.lastname: Akyuz
authors.forename: Sadakat
authors.initials: S
authors.lastname: Ozdil
authors.forename: Kadir
authors.initials: K
authors.lastname: Demir
authors.forename: Fatih
authors.initials: F
authors.lastname: Besisik
authors.forename: Güngör
authors.initials: G
authors.lastname: Boztas
authors.forename: Zeynel
authors.initials: Z
authors.lastname: Mungan
authors.forename: Sabahattin
authors.initials: S
authors.lastname: Kaymakoglu
authors.forename: Atilla
authors.initials: A
authors.lastname: Okten
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006530:Hepatorenal Syndrome / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D000077585:Terlipressin; D014421:Turkey / Q000453:epidemiology; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D000418:Albumins; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin; D003404:Creatinine